Jeremy P. Gygi,Cole Maguire,Ravi K. Patel,Pramod Shinde,Anna Konstorum,Casey P. Shannon,Leqi Xu,Annmarie Hoch,Naresh Doni Jayavelu,Elias K. Haddad,Elaine F. Reed,Monica Kraft,Grace A. McComsey,Jordan P. Metcalf,Al Ozonoff,Denise Esserman,Charles B. Cairns,Nadine Rouphael,Steven E. Bosinger,Seunghee Kim-Schulze,Florian Krammer,Lindsey B. Rosen,Harm van Bakel,Michael Wilson,Walter L. Eckalbar,Holden T. Maecker,Charles R. Langelier,Hanno Steen,Matthew C. Altman,Ruth R. Montgomery,Ofer Levy,Esther Melamed,Bali Pulendran,Joann Diray-Arce,Kinga K. Smolen,Gabriela K. Fragiadakis,Patrice M. Becker,Rafick P. Sekaly,Lauren I.R. Ehrlich,Slim Fourati,Bjoern Peters,Steven H. Kleinstein,Leying Guan

Abstract:BACKGROUND. Patients hospitalized for COVID-19 exhibit diverse clinical outcomes, with outcomes for some individuals diverging over time even though their initial disease severity appears similar to that of other patients. A systematic evaluation of molecular and cellular profiles over the full disease course can link immune programs and their coordination with progression heterogeneity. METHODS. We performed deep immunophenotyping and conducted longitudinal multiomics modeling, integrating 10 assays for 1,152 Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study participants and identifying several immune cascades that were significant drivers of differential clinical outcomes. RESULTS. Increasing disease severity was driven by a temporal pattern that began with the early upregulation of immunosuppressive metabolites and then elevated levels of inflammatory cytokines, signatures of coagulation, formation of neutrophil extracellular traps, and T cell functional dysregulation. A second immune cascade, predictive of 28-day mortality among critically ill patients, was characterized by reduced total plasma Igs and B cells and dysregulated IFN responsiveness. We demonstrated that the balance disruption between IFN-stimulated genes and IFN inhibitors is a crucial biomarker of COVID-19 mortality, potentially contributing to failure of viral clearance in patients with fatal illness. CONCLUSION. Our longitudinal multiomics profiling study revealed temporal coordination across diverse omics that potentially explain the disease progression, providing insights that can inform the targeted development of therapies for patients hospitalized with COVID-19, especially those who are critically ill. TRIAL REGISTRATION. ClinicalTrials.gov NCT04378777. FUNDING. NIH (5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-18); NIAID, NIH (3U19AI1289130, U19AI128913-04S1, and R01AI122220); and National Science Foundation (DMS2310836).

Immune response in COVID-19: what is next?

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

COVID-19 infection: the perspectives on immune responses

Immune-Cell-Based Therapy for COVID-19: Current Status

COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas

Large-scale single-cell analysis reveals critical immune characteristics of COVID-19 patients

Identification of Distinct Immune Cells Associated with Various Clinical Presentations of COVID-19

Single-cell landscape of immunological responses in patients with COVID-19

A Landscape Study on COVID-19 Immunity at the Single-Cell Level

Unique immunological profile in patients with COVID-19

Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI)

Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis

Transcriptional and proteomic insights into the host response in fatal COVID-19 cases

Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality

Immune reactivity during COVID-19: Implications for treatment

Imaging Mass Cytometric Analysis of Postmortem Tissues Reveals Dysregulated Immune Cell and Cytokine Responses in Multiple Organs of COVID-19 Patients

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

COVID-19: Imbalanced Cell-Mediated Immune Response Drives to Immunopathology

Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions

Single-cell landscape of immunological responses in COVID-19 patients

A single-cell atlas of the peripheral immune response in patients with severe COVID-19